TrialThe Journal of dermatology2021

A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.

Tomoko Fujimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.